The following video is part of our "Motley Fool Conversations" series, in which advisor James Early and senior technology analyst Eric Bleeker discuss topics across the investing world.
In today's edition, James takes a look at the pharma world and keys in on a phrase that should strike fear into any pharma investor's heart: the dreaded "patent cliff." He's particularly weary that AstraZeneca and Eli Lilly, two companies that face looming patent cliffs, might look to ill-conceived deals in coming years. James recommends that pharma investors instead look to both Johnson & Johnson and GlaxoSmithKline.
One of the best reasons to invest in pharma is the solid dividends paid out by the companies. For example, James' recommendation in this video, as well as those in this report: "Secure Your Future With 11 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost! Just click here to discover the winners we've picked.